Compare GDRX & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | AVLN |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2026 |
| Metric | GDRX | AVLN |
|---|---|---|
| Price | $3.60 | $26.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $3.95 | ★ $61.80 |
| AVG Volume (30 Days) | ★ 878.1K | 264.7K |
| Earning Date | 11-03-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $796,853,000.00 | N/A |
| Revenue This Year | $0.20 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | $119.33 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $22.24 |
| 52 Week High | $4.05 | $40.17 |
| Indicator | GDRX | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 49.09 |
| Support Level | $3.26 | $26.81 |
| Resistance Level | $3.89 | $30.45 |
| Average True Range (ATR) | 0.12 | 1.74 |
| MACD | 0.03 | 0.37 |
| Stochastic Oscillator | 91.46 | 81.07 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.